Avidis

Avidis aims to create immunotherapeutics through its unique protein engineering technology platform, aXent™. The company was founded in 2000 as a spin-off from the Medical Research Council, UK and Cambridge University, UK. Avidis' technology enables immunization without adjuvants and thus the creation of new vaccines and immunotherapeutics.